Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
76 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2014', provides an overview of the Mycobacterium Tuberculosis Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Mycobacterium Tuberculosis Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mycobacterium Tuberculosis Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Mycobacterium Tuberculosis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Mycobacterium Tuberculosis Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mycobacterium Tuberculosis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mycobacterium Tuberculosis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Mycobacterium Tuberculosis Infections Overview 8 Therapeutics Development 9 Pipeline Products for Mycobacterium Tuberculosis Infections - Overview 9 Pipeline Products for Mycobacterium Tuberculosis Infections - Comparative Analysis 10 Mycobacterium Tuberculosis Infections - Therapeutics under Development by Companies 11 Mycobacterium Tuberculosis Infections - Therapeutics under Investigation by Universities/Institutes 13 Mycobacterium Tuberculosis Infections - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Mycobacterium Tuberculosis Infections - Products under Development by Companies 18 Mycobacterium Tuberculosis Infections - Products under Investigation by Universities/Institutes 19 Mycobacterium Tuberculosis Infections - Companies Involved in Therapeutics Development 20 Shionogi & Co., Ltd. 20 AstraZeneca PLC 21 GlaxoSmithKline plc 22 Novartis AG 23 Oragenics, Inc. 24 Archivel Farma S.L. 25 NovoBiotic Pharmaceuticals, LLC 26 Spring Bank Pharmaceuticals, Inc. 27 Bioversys AG 28 Univalue Valorizacion, S.L. 29 GlobalAcorn 30 Mycobacterium Tuberculosis Infections - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 RUTI - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ID-93 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 MU-1140 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BV-6481 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecule for Staphylococcus Aureus Infections and Mycobacterium Tuberculosis Infections - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Inhibit Gyrase for Mycobacterium Tuberculosis Infections - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 rAMtb-SIVgag Vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 NITD-349 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Inhibit Structural Protein FtsZ for Bacterial Infections - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules for Bacterial and Viral Infections - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 SB-9922 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Novo-23 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Thuggacine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 KKL-35 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecule for Tuberculosis - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Small Molecule 2 for Tuberculosis - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecules to Inhibit CysK1 for Tuberculosis - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 GA-3MEP-TB - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecules for Mycobacterium Tuberculosis Infections - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Small Molecules for Mycobacterium Tuberculosis - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Small Molecules for Infectious Disease - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Small Molecules for Multiresistant Mycobacterium Tuberculosis Infections - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Synthetic Peptide for Bacterial Infections - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Mycobacterium Tuberculosis Infections - Recent Pipeline Updates 68 Mycobacterium Tuberculosis Infections - Dormant Projects 69 Mycobacterium Tuberculosis Infections - Product Development Milestones 70 Featured News & Press Releases 70 Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis 70 Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 70 Jun 17, 2013: Researchers Identify New Compound Effective Against Persistent And Drug-Resistant Tuberculosis 71 Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 73 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 76 Disclaimer 76
List of Tables Number of Products under Development for Mycobacterium Tuberculosis Infections, H2 2014 9 Number of Products under Development for Mycobacterium Tuberculosis Infections - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Comparative Analysis by Unknown Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Products under Investigation by Universities/Institutes, H2 2014 19 Mycobacterium Tuberculosis Infections - Pipeline by Shionogi & Co., Ltd., H2 2014 20 Mycobacterium Tuberculosis Infections - Pipeline by AstraZeneca PLC, H2 2014 21 Mycobacterium Tuberculosis Infections - Pipeline by GlaxoSmithKline plc, H2 2014 22 Mycobacterium Tuberculosis Infections - Pipeline by Novartis AG, H2 2014 23 Mycobacterium Tuberculosis Infections - Pipeline by Oragenics, Inc., H2 2014 24 Mycobacterium Tuberculosis Infections - Pipeline by Archivel Farma S.L., H2 2014 25 Mycobacterium Tuberculosis Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2014 26 Mycobacterium Tuberculosis Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014 27 Mycobacterium Tuberculosis Infections - Pipeline by Bioversys AG, H2 2014 28 Mycobacterium Tuberculosis Infections - Pipeline by Univalue Valorizacion, S.L., H2 2014 29 Mycobacterium Tuberculosis Infections - Pipeline by GlobalAcorn, H2 2014 30 Assessment by Monotherapy Products, H2 2014 31 Number of Products by Stage and Target, H2 2014 33 Number of Products by Stage and Mechanism of Action, H2 2014 35 Number of Products by Stage and Route of Administration, H2 2014 37 Number of Products by Stage and Molecule Type, H2 2014 39 Mycobacterium Tuberculosis Infections Therapeutics - Recent Pipeline Updates, H2 2014 68 Mycobacterium Tuberculosis Infections - Dormant Projects, H2 2014 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.